Monitor the randomized Phase 2 MSS CRC data readout in H1 2027 as the primary catalyst. The extended cash runway into late 2028 removes near-term financing risk, but the widening net loss and significant share dilution from the April 2026 offering warrant caution. Watch for any partnership milestones or updates from the Sanofi and Incyte collaborations.
Price Chart
Executive Summary
Adagene reported H1 2026 financial results showing a net loss of $16.4M (vs $13.5M in H1 2025) with $1.6M in licensing revenue. The company highlighted strong clinical data for muzastotug in MSS CRC (31% ORR at 20mg/kg) and HCC (66.7% ORR), and extended its cash runway into late 2028 via a $70M April 2026 offering. The randomized Phase 2 trial in MSS CRC is on track with results expected in H1 2027, and a potential registration trial is planned for 2027. The filing is neutral as the clinical progress is offset by widening losses and the pre-revenue stage, with the cash runway being the key positive.
Key Facts
- Net loss of $16.4M for H1 2026 vs $13.5M in H1 2025
- Cash and cash equivalents of $127.9M as of June 30, 2026, providing runway into late 2028
- Licensing and collaboration revenue of $1.6M in H1 2026 vs nil in H1 2025
- R&D expenses increased 16.2% to $14.0M, driven by muzastotug development
- Muzastotug achieved 31% confirmed ORR in MSS CRC at 20mg/kg dosing
- Randomized Phase 2 trial in MSS CRC on track with results expected in H1 2027
- Underwritten public offering in April 2026 raised ~$70M in gross proceeds
- Ordinary shares outstanding increased from 59.2M to 83.9M due to equity offerings
Financial Impact
Net loss widened by $2.9M YoY; cash position strengthened by $53.4M from equity offerings
Risk Factors
- Widening net losses with no product revenue
- Significant share dilution from April 2026 offering (23.3M ordinary shares)
- Clinical trial execution risk for Phase 2 MSS CRC study
- Dependence on partnership milestones for revenue generation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-094468 |
| Document: adag-20260812xex99d1.htm | 0001104659-26-094468 |
| Document: adag-20260812x6k.htm | 0001104659-26-094468 |
| Document: 0001104659-26-094468-index-headers.html | 0001104659-26-094468 |
| Document: 0001104659-26-094468-index.html | 0001104659-26-094468 |
| Document: 0001104659-26-094468.txt | 0001104659-26-094468 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $3.20 | awaiting T+60 | — | $2.41 (−24.69%) |
Sep 22, 2026 4w ago | 6-K | $3.23 | awaiting T+60 | — | $2.41 (−25.39%) |
Sep 10, 2026 6w ago | 6-K | $3.31 | awaiting T+60 | — | $2.41 (−27.19%) |
Sep 9, 2026 6w ago | 6-K | $3.27 | awaiting T+60 | — | $2.41 (−26.30%) |
Aug 16, 2026 10w ago | Institutional Cluster | $3.83 | awaiting T+60 | — | $2.41 (−37.08%) |
Aug 12, 2026 10w ago | 6-K | $3.75 | awaiting T+60 | — | $2.41 (−35.73%) |
Aug 12, 2026 10w ago | Press Release | $3.75 | awaiting T+60 | — | $2.41 (−35.73%) |
Jul 6, 2026 16w ago | 6-K | $3.93 $3.21 | ▼ −18.32% | ▼ −20.04% | $2.41 (−38.68%) |
Apr 17, 2026 27w ago | 6-K | $3.89 $3.67 | ▼ −5.66% | ▼ −12.43% | $2.41 (−38.05%) |
Apr 2, 2026 29w ago | 6-K | $3.99 $4.20 | ▼ −5.26% | ▲ +8.90% | $2.41 (+39.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers